Emergent Biosolutions Gross Profit 2007-2021 | EBS

Emergent Biosolutions gross profit from 2007 to 2021. Gross profit can be defined as the profit a company makes after deducting the variable costs directly associated with making and selling its products or providing its services.
Emergent Biosolutions Annual Gross Profit
(Millions of US $)
2020 $1,031
2019 $673
2018 $460
2017 $373
2016 $363
2015 $382
2014 $303
2013 $251
2012 $236
2011 $231
2010 $239
2009 $189
2008 $144
2007 $143
2006 $129
2005 $99
Emergent Biosolutions Quarterly Gross Profit
(Millions of US $)
2021-09-30 $226
2021-06-30 $170
2021-03-31 $244
2020-12-31 $386
2020-09-30 $265
2020-06-30 $265
2020-03-31 $116
2019-12-31 $228
2019-09-30 $204
2019-06-30 $142
2019-03-31 $99
2018-12-31 $157
2018-09-30 $104
2018-06-30 $135
2018-03-31 $64
2017-12-31 $132
2017-09-30 $105
2017-06-30 $66
2017-03-31 $71
2016-12-31 $118
2016-09-30 $103
2016-06-30 $62
2016-03-31 $79
2015-12-31 $115
2015-09-30 $123
2015-06-30 $99
2015-03-31 $45
2014-12-31 $86
2014-09-30 $106
2014-06-30 $76
2014-03-31 $35
2013-12-31 $79
2013-09-30 $69
2013-06-30 $65
2013-03-31 $37
2012-12-31 $79
2012-09-30 $56
2012-06-30 $57
2012-03-31 $43
2011-12-31 $94
2011-09-30 $48
2011-06-30 $72
2011-03-31 $17
2010-12-31 $86
2010-09-30 $62
2010-06-30 $51
2010-03-31 $39
2009-12-31 $42
2009-09-30 $35
2009-06-30 $63
2009-03-31 $49
2008-12-31 $29
2008-09-30 $46
2008-06-30 $35
2008-03-31 $35
2007-12-31 $72
2007-09-30 $32
2007-06-30 $17
2007-03-31 $21
2006-12-31 $74
2006-09-30 $35
2006-06-30 $10
2006-03-31 $9
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $2.254B $1.555B
Emergent BioSolutions Inc. is strongly committed to the highest standards of ethical conduct and corporate governance. These standards are consistent with their corporate culture. The company understands that adhering to sound principles of corporate governance is critical to earning and maintaining the trust of their customers, employees and shareholders. The foundation of the corporate governance principles and practices are built on their reputation for openness, integrity and accountability. These are the principles that guide Emergent BioSolutions everyday. They have in place policies and practices to ensure that their Company is managed with integrity and in their shareholders' best interests. In addition, they are committed to meeting the requirements of federal and state law and the rules of the New York Stock Exchange.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $125.010B 7.90
Bio-Rad Laboratories (BIO.B) United States $22.443B 45.55
QIAGEN (QGEN) Netherlands $12.357B 20.93
Biohaven Pharmaceutical Holding (BHVN) United States $6.783B 0.00
Arcus Biosciences (RCUS) United States $3.105B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.478B 0.00
Myovant Sciences (MYOV) United Kingdom $1.368B 0.00
Zymeworks (ZYME) Canada $0.861B 0.00
Ambrx Biopharma (AMAM) United States $0.337B 0.00
SQZ Biotechnologies (SQZ) United States $0.319B 0.00
Enzo Biochem (ENZ) United States $0.162B 15.90